Survival benefit of higher fraction dose delivered by three-dimensional conformal radiotherapy in hepatocellular carcinoma smaller than 10 cm in size

References

• Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Volume VII. IARC Sci Publ. 1997;VII(143):i-xxxiv, 1–1240.
   Google Scholar
• Center KLCSGaNC. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15(3):391–423. doi:10.3350/kjhep.2009.15.3.39119783891
   PubMedGoogle Scholar
• Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 2009;44(Suppl 19):119–121. doi:10.1007/s00535-008-2244-z19148805
   PubMedGoogle Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. doi:10.1055/s-0030-124713320175034
   PubMed Web of Science ®Google Scholar
• Chinese Anti-Cancer Association. Diagnostic criteria for primary liver cancer. Chin J Hepatol. 2000;8(3):135.
   Google Scholar
• Ishii H, Furuse J, Kinoshita T, et al. Hepatectomy for hepatocellular carcinoma patients who meet the Milan criteria. Hepato-gastroenterology. 2008;55(82–83):621–626.18613420
   PubMedGoogle Scholar
• Benson AB 3rd, D‘Angelica MI, Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563–573.28476736
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Boas FE. Radiation segmentectomy for hepatocellular carcinoma: readyfor prime time? Radiology. 2018;287(3):1059–1060. doi:10.1148/radiol.201818016329688156
   PubMed Web of Science ®Google Scholar
• Kagawa T, Koizumi J, Kojima S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116(15):3638–3644. doi:10.1002/cncr.2514220564097
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050–1058. doi:10.1148/radiol.201817176829688155
   PubMed Web of Science ®Google Scholar
• Lim DH, Lee H, Park HC, et al. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients withsmall hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol. 2013;36(2):162–166. doi:10.1097/COC.0b013e3182438dae22391433
   PubMed Web of Science ®Google Scholar
• Jung J, Kong M, Hong SE. Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis. Onco Targets Ther. 2014;7:1769–1775. doi:10.2147/OTT.S6961825328410
   PubMed Web of Science ®Google Scholar
• Zhou ZH, Liu LM, Chen WW, et al. Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol. 2007;80(951):194–201. doi:10.1259/bjr/3352159617038412
   PubMed Web of Science ®Google Scholar
• Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10(5):307–316.15530260
   PubMed Web of Science ®Google Scholar
• Wu DH, Zhi FC, Chen LH. Evaluating the efficacy of transcatheter arterial chemoembolization combined with hypofractionated 3- dimensional conformal radiotherapy for hepatocellular carcinoma. Chinese J Digestion. 2004.
   Google Scholar
• Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005;25(6):1189–1196. doi:10.1111/j.1478-3231.2005.01170.x16343071
   PubMed Web of Science ®Google Scholar
• Liu MZ, Wang XS, Cai L, et al. [External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer]. Chin J Cancer. 2005;24(1):82–86.
   Google Scholar
• Liao XF, Hui-Juan HE, Zhou ZS. Three-dimensional conformal radiotherapy combined with interventional therapy in treatment of primary hepatocellular carcinoma. J Pract Oncol. 2010;25(6):681–684.
   Google Scholar
• Chen WJ, Yuan SF, Zhu LJ, Sun XN, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. J BUON. 2014;19(3):692–697.25261654
   PubMed Web of Science ®Google Scholar
• Wang C, Li S, Sun A, et al. The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma. Tumour Biol. 2015;36(7):4967–4972. doi:10.1007/s13277-015-3144-525773387
   PubMedGoogle Scholar
• Hou JZ, Zeng ZC, Wang BL, Yang P, Zhang JY, Mo HF. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT. Jpn J Clin Oncol. 2016;46(4):357–362. doi:10.1093/jjco/hyv20526802166
   PubMed Web of Science ®Google Scholar
• Jiang JH, Guo Z, Lu HF, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis. World J Gastroenterol. 2015;21(15):4627–4634. doi:10.3748/wjg.v21.i15.462725914472
   PubMed Web of Science ®Google Scholar
• Chiche L, Menahem B, Bazille C, et al. Recurrence of hepatocellular carcinoma in noncirrhotic liver after hepatectomy. World J Surg. 2013;37(10):2410–2418. doi:10.1007/s00268-013-2127-123775516
   PubMed Web of Science ®Google Scholar
• Truant S, Boleslawski E, Duhamel A, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012;38(12):1189–1196. doi:10.1016/j.ejso.2012.07.11222863304
   PubMed Web of Science ®Google Scholar
• Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Invest New Drugs. 2011;29(6):1360–1369. doi:10.1007/s10637-011-9726-121809025
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011;18(7):1955–1963. doi:10.1245/s10434-010-1540-z21240562
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086–1092. doi:10.1002/lt.2047216123959
   PubMed Web of Science ®Google Scholar
• Bae SH, Kim MS, Cho CK, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona clinic liver cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28(2):213–219. doi:10.3346/jkms.2013.28.2.21323400333
   PubMed Web of Science ®Google Scholar
• Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40(3):225–235. doi:10.1007/s00535-005-1566-315830281
   PubMed Web of Science ®Google Scholar
• Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82:2004–2011. doi:10.1016/j.ijrobp.2011.03.01921621346
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739. doi:10.1016/S0140-6736(02)08649-X12049862
   PubMed Web of Science ®Google Scholar
• Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008;19(6):862–869. doi:10.1016/j.jvir.2008.02.01318503900
   PubMed Web of Science ®Google Scholar
• Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol. 2016;34(17):2046–2053. doi:10.1200/JCO.2015.64.082126834067
   PubMed Web of Science ®Google Scholar